Nodular Lymphocyte-predominant Hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Nodular Lymphocyte-predominant Hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial [Phase 2]
A National Cancer Institute–sponsored Phase 2 trial (NORM) is evaluating rituximab versus mosunetuzumab in nodular lymphocyte-predominant ly…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
A clinical trial update noting that study NCT06098430 is recruiting to assess patient-reported outcomes and quality of life in adults and ch…
-
CLINICAL_TRIALS trial_result · 2021-04-08Clinical Trial Update: Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL) [Phase 2]
Phase 2 trial update of ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) has completed.
-
CLINICAL_TRIALS trial_result · 2017-04-20Clinical Trial Update: Rituximab in Treating Patients With Hodgkin's Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating rituximab in Hodgkin lymphoma has completed; results were posted in 2017.
-
CLINICAL_TRIALS trial_result · 2015-11-02Clinical Trial Update: Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) [Phase 2]
The document notes the completion of a Phase 2 trial of ofatumumab in relapsed nodular lymphocyte predominant Hodgkin lymphoma conducted by …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.